Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 8.01 (Other Events). FDA review-jurisdiction transfer requested from Ophthalmology to Hematologic Malignancies 2 for ADX-2191’s PVRL program.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA review-jurisdiction transfer requested from Ophthalmology to Hematologic Malignancies 2 for ADX-2191’s PVRL program
- SPA protocol withdrawn, eliminating prior FDA agreement on trial design and planned analysis
- Planned PVRL trial on hold pending FDA decision, with clinical program expected to require redesign
- Potentially larger, longer, costlier trial could delay NDA resubmission, approval and orphan-drug exclusivity
- Regulatory delays could shorten cash runway, accelerate financing needs and pressure ALDX shares
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.